Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Current Assets (2017 - 2025)

Fennec Pharmaceuticals filings provide 9 years of Current Assets readings, the most recent being $67.0 million for Q4 2025.

  • On a quarterly basis, Current Assets rose 51.94% to $67.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $67.0 million, a 51.94% increase, with the full-year FY2025 number at $67.0 million, up 51.94% from a year prior.
  • Current Assets hit $67.0 million in Q4 2025 for Fennec Pharmaceuticals, up from $46.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $68.2 million in Q1 2024 to a low of $15.6 million in Q2 2022.
  • Median Current Assets over the past 5 years was $27.9 million (2021), compared with a mean of $35.6 million.
  • Biggest five-year swings in Current Assets: crashed 44.6% in 2022 and later soared 221.62% in 2024.
  • Fennec Pharmaceuticals' Current Assets stood at $22.4 million in 2021, then increased by 19.39% to $26.7 million in 2022, then grew by 0.49% to $26.9 million in 2023, then skyrocketed by 64.29% to $44.1 million in 2024, then surged by 51.94% to $67.0 million in 2025.
  • The last three reported values for Current Assets were $67.0 million (Q4 2025), $46.1 million (Q3 2025), and $40.8 million (Q2 2025) per Business Quant data.